Multiple Myeloma · Active Clinical Trials
As of 2026-10-21, the full China registry snapshot contains 64 active multiple myeloma interventional trials across 31 provincial-level regions and 316 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
Found 14 active clinical trials(15 matching total)
View CAR-T LandscapeAn Early Exploratory Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Beijing Gobroad Hospital
Target / Modality
Dual-target CAR-T cell therapy targeting GPRC5D and BCMA
A Phase I/II Clinical Study of GC012F Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) 等 10 家
Target / Modality
CAR-T targeting both BCMA and CD19
A Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Locations & Centers
Cancer Hospital, Chinese Academy of Medical Sciences
Target / Modality
In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital 等 10 家
Target / Modality
Autologous BCMA/CD19 dual-targeting CAR-T
A Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital 等 25 家
Target / Modality
BCMA-targeted CAR-T cell therapy
A Randomized Controlled Phase III Clinical Study of Equecabtagene Autoleucel Injection in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Ruijin Hospital, Shanghai Jiao Tong University School of Medicine 等 28 家
Target / Modality
CAR-T
A Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Target / Modality
BCMA-targeting CAR-T cell therapy
A Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Locations & Centers
Cancer Hospital Chinese Academy of Medical Sciences
Target / Modality
In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
An Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Locations & Centers
Zhongshan Hospital, Xiamen University
Target / Modality
Allogeneic universal CAR-T targeting BCMA/GPRC5D
A Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of SWK001 in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital of USTC
Target / Modality
Autologous BCMA/CD19 dual-targeting CAR-T
An Early Exploratory Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Locations & Centers
Chinese PLA General Hospital (301 Hospital)
Target / Modality
CD19, BCMA dual-target in vivo CAR-T
An Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital 等 8 家
Target / Modality
GPRC5D-targeted CAR-T
In Vivo-Generated PICX Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Target / Modality
Relapsed/refractory multiple myeloma (RRMM)
A Phase Ib/II Clinical Study of CBM.BCMA Chimeric Antigen Receptor T-cell Injection (C-CAR088) in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)
Target / Modality
Autologous anti-BCMA CAR-T
A Phase I Clinical Study of Chimeric Antigen Receptor T-Cell (C-4-29) Formulation for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、West China Hospital, Sichuan University、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Target / Modality
Autologous anti-BCMA CAR-T